Oral Bacteria May Diagnose Pancreatic Cancer
|
By LabMedica International staff writers Posted on 04 Jun 2014 |

Image: The anaerobic bacteria Leptotrichia species, Gram-stain from blood culture (Photo courtesy of Mike Dyall-Smith).
Patients with pancreatic cancer have a different and distinct profile of specific bacteria in their saliva compared to healthy controls and even patients with other cancers or pancreatic diseases.
Patients diagnosed in the early stages of pancreatic cancer have a 5-year survival rate of 21.5%, but unfortunately symptoms do not appear until after the cancer has become untreatable in the vast majority of cases.
Scientists from San Diego State University (CA, USA) compared the diversity of saliva bacteria across 131 patients, 63 females and 68 males, being treated at the University of California, San Diego (UCSD) Moores Cancer Center (La Jolla, CA, USA). Of these patients, 14 had been diagnosed with pancreatic cancer, 13 with pancreatic disease, 22 with other forms of cancer, and 10 were disease free.
The results of the study found that patients diagnosed with pancreatic cancer had higher levels of two particular oral bacteria, Leptotrichia and Campylobacter, when compared to any other healthy or diseased state including noncancerous pancreatic disease. Those with pancreatic cancer also had lower levels of Streptococcus, Treponema, and Veillonella. These findings could form the basis for a test to diagnose the pancreatic cancer in its early stages.
Pedro Torres, BS, the coauthor of the study with Scott T. Kelley, PhD, said, “Our studies suggest that ratios of particular types of bacteria found in saliva may be indicative of pancreatic cancer. The results also suggest the presence of a consistently distinct microbial profile for pancreatic cancer. We may be able to detect pancreatic cancer at its early stages by taking individuals’ saliva and looking at the ratios of these bacteria.”
In the USA, approximately 40,000 people die every year due to pancreatic adenocarcinoma, making it the fourth leading cause of cancer related death. The study was presented on May 18, 2014, at the Annual meeting of the American Society for Microbiology held May 17–20, 2014, in Boston (MA, USA).
Related Links:
San Diego State University
Moores Cancer Center
Patients diagnosed in the early stages of pancreatic cancer have a 5-year survival rate of 21.5%, but unfortunately symptoms do not appear until after the cancer has become untreatable in the vast majority of cases.
Scientists from San Diego State University (CA, USA) compared the diversity of saliva bacteria across 131 patients, 63 females and 68 males, being treated at the University of California, San Diego (UCSD) Moores Cancer Center (La Jolla, CA, USA). Of these patients, 14 had been diagnosed with pancreatic cancer, 13 with pancreatic disease, 22 with other forms of cancer, and 10 were disease free.
The results of the study found that patients diagnosed with pancreatic cancer had higher levels of two particular oral bacteria, Leptotrichia and Campylobacter, when compared to any other healthy or diseased state including noncancerous pancreatic disease. Those with pancreatic cancer also had lower levels of Streptococcus, Treponema, and Veillonella. These findings could form the basis for a test to diagnose the pancreatic cancer in its early stages.
Pedro Torres, BS, the coauthor of the study with Scott T. Kelley, PhD, said, “Our studies suggest that ratios of particular types of bacteria found in saliva may be indicative of pancreatic cancer. The results also suggest the presence of a consistently distinct microbial profile for pancreatic cancer. We may be able to detect pancreatic cancer at its early stages by taking individuals’ saliva and looking at the ratios of these bacteria.”
In the USA, approximately 40,000 people die every year due to pancreatic adenocarcinoma, making it the fourth leading cause of cancer related death. The study was presented on May 18, 2014, at the Annual meeting of the American Society for Microbiology held May 17–20, 2014, in Boston (MA, USA).
Related Links:
San Diego State University
Moores Cancer Center
Latest Pathology News
- FDA Clears AI Digital Pathology Tool for Breast Cancer Risk Stratification
- New AI Tool Reveals Hidden Genetic Signals in Routine H&E Slides
- AI System Analyzes Routine Pathology Slides to Predict Cancer Outcomes
- New Tissue Mapping Approach Identifies High-Risk Form of Diabetic Kidney Disease
- Multimodal AI Tool Predicts Genetic Alterations to Guide Breast Cancer Treatment
- Interpretable AI Reveals Hidden Cellular Features from Microscopy Images
- Tumor Immune Structure Predicts Response to Immunotherapy in Melanoma
- Plug-and-Play AI Pathology System Classifies Multiple Cancers from Few Slides
- AI-Based Assays Support Risk Stratification in Prostate and Breast Cancer
- AI Pathology Model Predicts Immunotherapy Response in Lung Cancer
- Study Reveals Moleclar Mechanism Driving Aggressive Skin Cancer
- AI Precision Tests Deliver Cancer Risk Insights from Routine H&E Slides
- Collaboration Applies AI Pathology to Predict Response to Antibody-Drug Conjugates
- Biomarker Predicts Immunotherapy Response and Prognosis in Colorectal Cancer
- AI Improves Completeness of Complex Cancer Pathology Reports
- AI Tool Predicts Chemotherapy Response in Small Cell Lung Cancer
Channels
Clinical Chemistry
view channel
Blood-Based Alzheimer’s Test Gains CE Mark for Amyloid Pathology Detection
Alzheimer’s disease is the most common cause of dementia, yet confirmatory testing remains invasive and hard to access. Diagnosis currently takes an average of 3.5 years, and about 75% of people with dementia... Read more
FDA-Cleared Assay Enables Comprehensive Automated Testosterone Testing
Accurate evaluation of androgen status often requires concordant measurement of total testosterone, free testosterone, and sex hormone‑binding globulin. Reference methods such as equilibrium dialysis with... Read moreMolecular Diagnostics
view channel
Gene Panel Shows Promise for Predicting Chemotherapy Response in TNBC
Triple-negative breast cancer (TNBC) is an aggressive subtype commonly treated with chemotherapy, yet outcomes vary widely among patients. Understanding the tumor features that drive this variability remains... Read more
Realistic Mock Samples Aim to Speed Cervical Cancer Test Development
Cervical cancer remains highly preventable, yet screening access is limited in many low- and middle-income settings. Gold-standard tests for high-risk human papillomavirus (HPV) detect viral DNA or messenger... Read more
Molecular Marker Identifies Hormone Therapy Resistance Pathway in Prostate Cancer
Most prostate cancers depend on androgen signaling, making hormone suppression or blockade a central treatment strategy. Although many patients respond initially, tumors often adapt and eventually progress,... Read moreHematology
view channel
Stem Cell Biomarkers May Guide Precision Treatment in Acute Myeloid Leukemia
Acute myeloid leukemia (AML) is an aggressive blood cancer that most often affects older adults and still carries a poor prognosis despite therapeutic advances. Venetoclax-based regimens have improved... Read more
Advanced CBC-Derived Indices Integrated into Hematology Platforms
Diatron, a STRATEC brand, has introduced six advanced hematological indices on its Aquila, Aquarius 3, and Abacus 5 hematology analyzers. The new Research Use Only (RUO) indices include Neutrophil-to-Lymphocyte... Read moreImmunology
view channel
Routine TB Screening Test May Reveal Immune Aging and Mortality Risk
Immune aging is associated with weaker responses to vaccination, greater risks of infection, and higher levels of inflammation. Leveraging routinely ordered laboratory tests to quantify that responsiveness... Read more
Biomarkers and Molecular Testing Advance Precision Allergy Care
Allergic diseases often present with similar symptoms but can be driven by distinct biological mechanisms, making standardized care inefficient for many patients. Historically, individuals with pollen... Read morePathology
view channel
FDA Clears AI Digital Pathology Tool for Breast Cancer Risk Stratification
Risk assessment at diagnosis is central to guiding therapy for early-stage, hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) invasive breast cancer, where overtreatment... Read more
New AI Tool Reveals Hidden Genetic Signals in Routine H&E Slides
Pathologists worldwide rely on hematoxylin and eosin (H&E) slides to examine tissue architecture, yet these stains do not reveal the underlying molecular activity that often drives disease.... Read moreTechnology
view channel
Point-of-Care Testing Enhances Health Literacy and Self-Management in Chronic Disease
Limited access to general practitioners and pathology services can delay diagnosis and monitoring for people in regional and remote communities. Rapid, on-the-spot testing can shorten turnaround times... Read more
Fully Automated Sample-to-Insight Workflow Advances Latent TB Testing
Latent tuberculosis remains a substantial testing workload for clinical laboratories as screening programs expand. Despite this growth, only about 40% of testing has shifted from traditional skin tests... Read moreIndustry
view channel
Roche to Acquire PathAI for Up to $1.05 Billion to Strengthen AI Diagnostics Portfolio
Roche has entered into a definitive merger agreement to acquire PathAI, a company focused on digital pathology and artificial intelligence for pathology laboratories and the biopharma industry.... Read more








